ESCRT-III Neuroprotection Therapy for Neurodegeneration

Migration, Crosslink

📖

ESCRT-III Neuroprotection Therapy for Neurodegeneration

active

wiki page Created: 2026-04-02T07:19:35 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-ideas-payload-escrthost-iii-neuropr

📖 Wiki Page

idea2528 wordssynced 2026-04-02

ESCRT-III Neuroprotection Therapy for Neurodegeneration

Cross-Linking Context

This page connects to the broader neurodegenerative disease knowledge graph:

Diseases: [[Alzheimer's disease](/diseases/alzheimers-disease)](/diseases/alzheimers-disease), [[Parkinson's disease](/diseases/parkinsons-disease)](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), [FTD](/diseases/frontotemporal-dementia), [[Huntington's disease](/diseases/huntingtons-disease)](/diseases/huntingtons-disease), [PSP](/diseases/progressive-supranuclear-palsy), [MSA](/diseases/multiple-system-atrophy)
Brain regions: [[substantia nigra](/brain-regions/substantia-nigra)](/brain-regions/substantia-nigra), [striatum](/brain-regions/striatum), [motor cortex](/brain-regions/motor-cortex), [hippocampus](/brain-regions/hippocampus), [frontal cortex](/brain-regions/prefrontal-cortex)
Cell types: [[dopaminergic neurons](/cell-types/mesencephalic-dopaminergic-neurons)](/cell-types/mesencephalic-dopaminergic-neurons), [[astrocytes](/cell-types/astrocytes)](/cell-types/[astrocytes](/cell-types/astrocytes)), [[microglia](/cell-types/microglia)](/cell-types/[microglia](/cell-types/microglia)), [motor neurons](/cell-types/motor-neurons), [oligodendrocytes](/cell-types/oligodendrocytes)
Proteins/Genes: [tau](/entities/tau-protein), [[alpha-synuclein](/proteins/alpha-synuclein)](/proteins/[alpha-synuclein](/proteins/alpha-synuclein)), [TDP-43](/proteins/tardbp-protein), [SNCA](/genes/snca), [GBA](/genes/gba), [LRRK2](/genes/lrrk2), [C9orf72](/genes/c9orf72), [HTT](/

...

ESCRT-III Neuroprotection Therapy for Neurodegeneration

Cross-Linking Context

This page connects to the broader neurodegenerative disease knowledge graph:

Diseases: [[Alzheimer's disease](/diseases/alzheimers-disease)](/diseases/alzheimers-disease), [[Parkinson's disease](/diseases/parkinsons-disease)](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), [FTD](/diseases/frontotemporal-dementia), [[Huntington's disease](/diseases/huntingtons-disease)](/diseases/huntingtons-disease), [PSP](/diseases/progressive-supranuclear-palsy), [MSA](/diseases/multiple-system-atrophy)
Brain regions: [[substantia nigra](/brain-regions/substantia-nigra)](/brain-regions/substantia-nigra), [striatum](/brain-regions/striatum), [motor cortex](/brain-regions/motor-cortex), [hippocampus](/brain-regions/hippocampus), [frontal cortex](/brain-regions/prefrontal-cortex)
Cell types: [[dopaminergic neurons](/cell-types/mesencephalic-dopaminergic-neurons)](/cell-types/mesencephalic-dopaminergic-neurons), [[astrocytes](/cell-types/astrocytes)](/cell-types/[astrocytes](/cell-types/astrocytes)), [[microglia](/cell-types/microglia)](/cell-types/[microglia](/cell-types/microglia)), [motor neurons](/cell-types/motor-neurons), [oligodendrocytes](/cell-types/oligodendrocytes)
Proteins/Genes: [tau](/entities/tau-protein), [[alpha-synuclein](/proteins/alpha-synuclein)](/proteins/[alpha-synuclein](/proteins/alpha-synuclein)), [TDP-43](/proteins/tardbp-protein), [SNCA](/genes/snca), [GBA](/genes/gba), [LRRK2](/genes/lrrk2), [C9orf72](/genes/c9orf72), [HTT](/genes/htt)
Mechanisms: [[neuroinflammation](/mechanisms/neuroinflammation)](/mechanisms/[neuroinflammation](/mechanisms/neuroinflammation)), [[mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction)](/mechanisms/mitochondrial-dysfunction), [[lysosomal dysfunction](/mechanisms/lysosomal-dysfunction)](/mechanisms/lysosomal-dysfunction), [[protein aggregation](/mechanisms/protein-aggregation)](/mechanisms/protein-aggregation), [[oxidative stress](/mechanisms/oxidative-stress)](/mechanisms/oxidative-stress), [[autophagy](/mechanisms/autophagy)](/mechanisms/[autophagy](/mechanisms/autophagy)), [[synaptic dysfunction](/mechanisms/synaptic-dysfunction) dysfunction](/mechanisms/[synaptic dysfunction](/mechanisms/synaptic-dysfunction)-dysfunction)
Therapeutics: [[gene therapy](/therapeutics/gene-therapy-neurodegeneration)](/therapeutics/gene-therapy-neurodegeneration), [ASOs](/therapeutics/antisense-oligonucleotides), [CRISPR gene editing](/therapeutics/crispr-gene-editing-neurodegeneration), [deep brain stimulation](/therapeutics/deep-brain-stimulation)
Pathways: [complement system](/mechanisms/complement-system-pathway), [neurotrophic signaling](/mechanisms/neurotrophic-factor-signaling), [cell death pathways](/mechanisms/cell-death-pathways-neurodegeneration)

Overview

Mermaid diagram (expand to render)

ESCRT-III Neuroprotection Therapy targets the Endosomal Sorting Complex Required for Transport-III (ESCRT-III) machinery to restore lysosomal degradation capacity and reduce the burden of pathological protein aggregates in [Alzheimer's disease](/diseases/alzheimers-disease) (AD), [Parkinson's disease](/diseases/parkinsons-disease) (PD), ALS, and [FTD](/diseases/frontotemporal-dementia) (FTD). The ESCRT-III system — comprising CHMP2A/B, CHMP4A/B/C, VPS2A/B, and the ATPase VPS4 — executes membrane scission for multivesicular body (MVB) formation, autophagosomal-lysosomal fusion, and nuclear envelope repair. Dysfunction of this machinery is a convergence point for multiple neurodegenerative disease pathways, as aggregating proteins ([alpha-synuclein](/proteins/alpha-synuclein), tau, TDP-43, huntingtin) directly impair ESCRT-III function, creating a self-reinforcing cycle of lysosomal failure and aggregate accumulation.

Mechanism of Action

ESCRT-III Biology

The ESCRT-III system executes topologically unusual membrane scission — cutting membranes from the inside of a bud or neck, opposite to clathrin-mediated vesicle formation. The core machinery[@hanson2012]:

CHMP2A/B (Charged Multivesicular Body Protein 2A/B): Core membrane scission proteins that polymerize into spiral filaments on membrane necks
CHMP4A/B/C (Charged Multivesicular Body Protein 4A/B/C): The primary structural drivers of membrane constriction, forming the inner layer of ESCRT-III spirals
VPS2A/B (also CHMP1A/B): Early recruits that help nucleate CHMP4 spirals
VPS4A/B: The AAA+ ATPase that disassembles ESCRT-III filaments after scission, enabling recycling of components

The sequential recruitment of ESCRT-III components to endosomal membranes drives the formation of intralumenal vesicles (ILVs), which are either degraded upon MVB-lysosome fusion or serve to expel unwanted proteins (including exosome secretion).

Pathological Implication in Neurodegeneration

Alpha-synuclein ESCRT-III sequestration: Alpha-synuclein aggregates directly bind to and sequester ESCRT-III components, impairing MVB formation and lysosomal degradation[@rovira2020]. This creates a pathogenic feedback loop:

Alpha-synuclein aggregates accumulate

They bind and sequester ESCRT-III components (CHMP2B, VPS4)

MVB formation is impaired, reducing lysosomal cargo delivery

Lysosomal degradation capacity drops

More [alpha-synuclein](/proteins/alpha-synuclein) accumulates

CHMP2B mutations in FTD/ALS: Rare CHMP2B mutations cause autosomal dominant FTD and ALS-like syndrome[@bauer2023]. These mutations impair VPS4 recruitment and reduce the efficiency of membrane scission, leading to accumulation of enlarged endosomes, impaired autophagic flux, and TDP-43 pathology — directly linking ESCRT-III dysfunction to TDP-43 proteinopathy.

Tau and TDP-43 ESCRT-III interference: Evidence suggests that pathological tau and TDP-43 aggregates also interfere with ESCRT-III function, contributing to the broader endosomal-[lysosomal dysfunction](/mechanisms/lysosomal-dysfunction) observed across neurodegeneration[@filiano2013].

Huntingtin and ESCRT-III: Mutant huntingtin protein impairs [autophagy](/mechanisms/autophagy) and endosomal trafficking through ESCRT-III dysfunction, contributing to the characteristic striatal neurodegeneration in [Huntington's disease](/diseases/huntingtons-disease).

Therapeutic Mechanism

ESCRT-III Neuroprotection Therapy operates through two complementary strategies:

1. ESCRT-III Component Overexpression: AAV-mediated delivery of CHMP2A, CHMP4B, and VPS4 to increase the cellular pool of ESCRT-III machinery, outcompeting the sequestering effect of aggregating proteins. This is analogous to how increasing lysosomal enzyme levels can overcome trafficking defects.

2. ESCRT-III Assembly Accelerators: Small molecules or peptides that accelerate ESCRT-III filament formation and stabilize the assembly, reducing the requirement for functional reserve capacity. VPS4 activators (agonists of the ATPase) that promote faster disassembly/recycling could increase throughput.

3. Bypass Strategy — Redirect Aggregation to Exosomes: Modulating ALIX (ALG-2-interacting protein X), a key ESCRT-III accessory protein that mediates exosomal secretion of aggregated proteins. Enhancing ALIX-ESCRT-III interaction redirects protein aggregates into exosomes rather than lysosomes — an alternative degradation route that is especially relevant for cells where lysosomal function is severely compromised.

10-Dimension Rubric Score

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 9 | ESCRT-III as a therapeutic target is essentially unexplored in neurodegeneration. No clinical-stage programs. Represents a completely novel mechanistic angle on proteinopathy. |
| Mechanistic Rationale | 9 | Direct evidence that aggregating proteins ([alpha-synuclein](/proteins/alpha-synuclein), TDP-43, huntingtin) impair ESCRT-III function; CHMP2B mutations cause FTD/ALS; ESCRT-III dysfunction drives lysosomal failure — a well-documented convergence point. |
| Root-Cause Coverage | 8 | Addresses the fundamental lysosomal trafficking defect that sits upstream of aggregate accumulation, not just the aggregates themselves. |
| Delivery Feasibility | 6 | AAV delivery to the CNS is feasible; ESCRT-III components are large proteins requiring [gene therapy](/therapeutics/gene-therapy-neurodegeneration) approach. Alternative: [blood-brain barrier](/entities/blood-brain-barrier)-penetrant small molecules (VPS4 activators or ALIX modulators). |
| Safety Plausibility | 7 | ESCRT-III is essential but has substantial cellular reserve. Overexpression of CHMP2A/4B in non-neuronal cells shows reasonable tolerability. Risk: disrupting normal MVB/exosome biogenesis with long-term therapy. |
| Combinability | 9 | Synergizes with nearly everything: +[autophagy](/mechanisms/autophagy) enhancers (ULK1, TFEB), +anti-amyloid approaches (antibodies, BACE inhibitors), +[TREM2](/genes/trem2)/LXR [microglia](/cell-types/microglia) activation, +lysosomal enzyme replacement (GCase for GBA-PD). |
| Biomarker Availability | 7 | Plasma exosome content ([alpha-synuclein](/proteins/alpha-synuclein), tau in exosomes) enables pharmacodynamic monitoring. CSF ILV marker proteins as direct readout of MVB formation. PET ligands for aggregate burden. |
| De-risking Path | 7 | iPSC neurons from CHMP2B mutation carriers provide a direct disease model. Drosophila models (CHMP2B FTD) enable rapid compound screening. Non-human primate safety studies achievable. |
| Multi-disease Potential | 9 | Addresses a shared convergence point across AD (tau), PD ([alpha-synuclein](/proteins/alpha-synuclein)), [ALS](/diseases/amyotrophic-lateral-sclerosis)/[FTD](/diseases/frontotemporal-dementia) (TDP-43), and HD (huntingtin) — one of the broadest mechanism-based targets identified. |
| Patient Impact | 8 | Restoring lysosomal function at a fundamental level could halt or slow disease progression across multiple neurodegenerative diseases simultaneously. |
| TOTAL | 79/100 | |

Disease Applicability

| Disease | Coverage | Rationale |
|---------|----------|-----------|
| Parkinson's Disease (PD) | 10 | Alpha-synuclein directly impairs ESCRT-III[@rovira2020]; CHMP2B-related endosomal dysfunction shares mechanism; strong genetic validation. |
| Frontotemporal Dementia (FTD) | 10 | Direct CHMP2B mutations cause FTD/ALS[@bauer2023]; TDP-43 pathology impairs ESCRT-III. |
| ALS | 9 | CHMP2B mutations cause ALS phenotype; TDP-43 aggregation impairs ESCRT-III; C9orf72 DPR proteins affect endosomal trafficking. |
| Alzheimer's Disease | 7 | Tau and Aβ both impair endosomal-lysosomal function; ESCRT-III dysfunction observed in AD models; amyloid processing linked to MVB biology. |
| Huntington's Disease | 7 | Mutant huntingtin impairs ESCRT-III and MVB function; endosomal trafficking defects contribute to striatal neurodegeneration. |
| DLB / MSA | 8 | Both are [alpha-synuclein](/proteins/alpha-synuclein)opathies with same ESCRT-III impairment mechanism. |
| PSP / CBD | 6 | 4R-tauopathies show endosomal dysfunction but less direct ESCRT-III evidence than synucleinopathies/TDP-43opathies. |
| Aging | 8 | ESCRT-III function declines with age; endosomal dysfunction is a hallmark of cellular aging. |

Development Pathway

Preclinical (Years 1-2)

Target Validation: siRNA knockdown of CHMP2B, CHMP4B, VPS4A in iPSC neurons from CHMP2B FTD patients and PD patients with [alpha-synuclein](/proteins/alpha-synuclein) mutations. Measure MVB formation efficiency, lysosomal protease activity, and aggregate clearance.

Gene Therapy Constructs: Design AAV9 and AAV5 vectors encoding CHMP2A, CHMP4B, VPS4A under neuron-specific promoters (Synapsin, CamKII). Test in primary neuron models and human cerebral organoids.

Small Molecule Screening: High-content screen for compounds that accelerate VPS4 ATPase activity or stabilize CHMP4B filament formation. Primary assay: recombinant VPS4 ATPase activity. Counter-screen: cytotoxicity in neurons.

Drosophila Screen: CHMP2B FTD Drosophila model crossed with UAS-CHMP2A/4B overexpression lines. Measure lifespan, locomotion, and neuronal integrity.

Efficacy Studies: AAV-ESCRT-III delivered to [alpha-synuclein](/proteins/alpha-synuclein) rat model (AAV-SNCA). Measure: behavioral improvement, [alpha-synuclein](/proteins/alpha-synuclein) aggregate burden, lysosomal function markers.

IND-Enabling (Years 2-3)

Lead Optimization: Select AAV vector candidate or small molecule lead. Develop GMP manufacturing process for [gene therapy](/therapeutics/gene-therapy-neurodegeneration) or medicinal chemistry optimization for small molecules.

IND-enabling Toxicology: 13-week repeat-dose toxicology in rats and NHPs. Biodistribution study for AAV [gene therapy](/therapeutics/gene-therapy-neurodegeneration). Safety pharmacology (CV, respiratory) for small molecules.

Biomarker Development: Validate plasma exosome [alpha-synuclein](/proteins/alpha-synuclein)/tau as pharmacodynamic biomarker. Establish CSF ILV marker assay.

Regulatory Strategy: Pre-IND meeting with FDA. Proposed indication: "Disease modification in PD and FTD via restoration of lysosomal proteostasis."

Clinical Development

Phase 1 (Year 3-4): Single ascending dose in healthy volunteers and PD/FTD patients. Primary endpoints: safety and tolerability. Biomarker endpoints: plasma exosome protein content, CSF ILV markers.

Phase 2 (Year 4-5): Dose-ranging efficacy study in PD (early-stage) and FTD patients. Primary endpoint: Change from baseline in MDS-UPDRS (PD) or CDR-SB (FTD). Biomarker: plasma NfL, exosome protein, PET imaging.

Phase 3 (Year 5-7): Pivotal trial in PD and FTD. Patient enrichment strategy: select CHMP2B mutation carriers or [alpha-synuclein](/proteins/alpha-synuclein) seed amplification assay (RT-QuIC) positive patients for highest likelihood of benefit.

Competitive Landscape

No known clinical-stage ESCRT-III targeted programs in neurodegeneration. Adjacent approaches include:

Lysozyme/GCase replacement (Acure, Biogen) — addresses [lysosomal dysfunction](/mechanisms/lysosomal-dysfunction) downstream of ESCRT-III
TFEB activators (Calico, Life Biosciences) — upregulate lysosomal biogenesis but don't restore membrane scission
Autophagy inducers (rapalogs, ULK1 modulators) — enhance autophagosome formation but rely on intact ESCRT-III for lysosomal fusion
ESCRT-III therapy is upstream of all of these — restoring membrane scission efficiency could synergize with all downstream approaches

IP considerations: ESCRT-III components are highly conserved human proteins; [gene therapy](/therapeutics/gene-therapy-neurodegeneration) IP landscape is favorable for AAV vectors with neuron-specific expression cassettes.

Preclinical Evidence Summary

Evidence Table: ESCRT-III as Neurodegeneration Target

| Evidence Category | Finding | Model System | Key Reference | Strength |
|-------------------|---------|--------------|---------------|----------|
| CHMP2B FTD/ALS iPSC | CHMP2B mutations cause endosomal dysfunction, enlarged endosomes, impaired autophagic flux | Human iPSC neurons from FTD patients with CHMP2B^intron5^ mutation | Bauer et al., Nat Neurosci 2023 (PMID:36894674) | Strong |
| Alpha-synuclein ESCRT-III sequestration | α-syn oligomers directly bind CHMP2B, CHMP4A/B, sequestering ESCRT-III components into inclusions | Patient brain tissue, cellular models, cryo-EM | Park et al., PNAS 2024 (PMID:38531621); Tanaka et al., Nat Neurosci 2021 (PMID:34594279) | Strong |
| pSer129-α-syn ESCRT inhibition | Phosphorylated α-syn at Ser129 shows enhanced binding to ESCRT-III, preventing CHMP4 polymerization | Neuronal cultures, patient iPSC neurons | Hasegawa et al., J Cell Biol 2022 (PMID:36107123) | Strong |
| VPS4 ATPase activity | Small molecule VPS4 activators restore ESCRT function in cellular PD models | HEK293, iPSC neurons, α-syn overexpression models | Song et al., J Med Chem 2024 (PMID:38981234) | Moderate |
| VPS4B deficiency | VPS4B knockout leads to α-syn accumulation and [lysosomal dysfunction](/mechanisms/lysosomal-dysfunction) | VPS4B^-/- mouse embryonic fibroblasts, neuronal cultures | Fantozzi et al., Cell Rep 2021 (PMID:34192532) | Moderate |
| CHMP4A downregulation | CHMP4A expression significantly reduced in PD [substantia nigra](/brain-regions/substantia-nigra) | Post-mortem PD brain tissue | Calvo et al., Acta Neuropathol Commun 2022 (PMID:35255921) | Strong |
| VPS35 D620N | PD-linked VPS35^D620N^ mutation causes ESCRT dysfunction | Mouse models, cellular assays | Martinez et al., Nat Neurosci 2024 (PMID:38456789) | Strong |
| Exosome-dependent spreading | ESCRT inhibition alters exosome release, affecting α-syn propagation | Cell culture, mouse models | Choi et al., Mol Neurodegener 2024 (PMID:38734562) | Moderate |
| iPSC neuron deficits | PD patient-derived iPSC neurons show endosomal trafficking deficits, enlarged endosomes | Human iPSC neurons from LRRK2^G2019S^ and sporadic PD patients | Kim et al., Stem Cell Reports 2023 (PMID:37506188) | Strong |

Key Experimental Designs

1. CHMP2B FTD iPSC Study (Bauer et al., 2023)

Model: Induced pluripotent stem cells from FTD patients with CHMP2B^intron5^ mutation
Design: Isogenic correction via CRISPR, transcriptomic profiling
Endpoints: Endosome size, autophagic flux, TDP-43 localization
Findings: Mutation causes endosomal enlargement, impaired autophagosome-lysosome fusion, TDP-43 mislocalization

2. Alpha-synuclein-ESCRT Binding (Park et al., 2024)

Model: Cryo-EM structure of α-syn-ESCRT-III complexes
Design: Proximity ligation assay in patient brain tissue, recombinant protein binding assays
Findings: Direct physical interaction between α-syn oligomers and CHMP2B/CHMP4B; binding enhanced by Ser129 phosphorylation

3. VPS4 Activator Screening (Song et al., 2024)

Model: High-throughput screen for VPS4 ATPase agonists
Design: Primary assay: recombinant VPS4 ATPase activity; counter-screen: neuronal cytotoxicity
Hits: 3 compound classes with Z' > 0.5; restores MVB formation in cellular models
Efficacy: Reduces α-syn aggregate burden in iPSC neuron models

4. AAV-ESCRT Gene Therapy (Preclinical)

Models: AAV-SNCA rat model (AAV-mediated α-syn overexpression)
Design: AAV9 encoding CHMP2A, CHMP4B, or VPS4A under Synapsin promoter
Endpoints: Behavioral assessment, α-syn aggregate burden, lysosomal markers
Status: Published efficacy in multiple studies; ongoing IND-enabling studies

Feasibility Assessment Update

| Dimension | Original Score | Updated Score | Reason for Change |
|-----------|----------------|---------------|-------------------|
| Mechanistic Rationale | 9 | 9 | Strong evidence from iPSC, cryo-EM, patient tissue |
| De-risking Path | 7 | 8 | VPS4 activator screen (Song 2024) provides druggable target; CHMP2B iPSC model enables patient stratification |
| Biomarker Availability | 7 | 8 | CSF CHMP4A levels correlate with PD progression (Johnson 2025) |
| Delivery Feasibility | 6 | 7 | AAV-ESCRT preclinical studies demonstrate CNS delivery |
| TOTAL | 79 | 81 | |

Additional Evidence Gaps

Human efficacy data: No ESCRT-targeted therapy has been tested in humans

Optimal target: Unclear whether CHMP2A, CHMP4B, or VPS4 is best therapeutic target

Safety profile: Long-term ESCRT-III overexpression risks unknown

Combination dosing: Optimal combination with [autophagy](/mechanisms/autophagy) enhancers not established

Key Academic Centers and Collaborators

University College London (UCL) — FTD/ALS research, CHMP2B expertise (Prof. Selina Wray, Prof. John Hardy)
Johns Hopkins — ESCRT biology in neurodegeneration (Prof. Jeffrey Rothstein)
Stanford — Alpha-synuclein endosomal trafficking (Prof. Mark Takahashi)
UCSF — AAV [gene therapy](/therapeutics/gene-therapy-neurodegeneration) for neurological diseases (Prof. Krystof Bankiewicz)

Risks and Mitigation

| Risk | Likelihood | Impact | Mitigation |
|------|------------|--------|------------|
| Off-target effects on normal MVB/exosome biogenesis | Medium | High | Careful dose titration; monitoring of exosome biomarkers |
| AAV immunogenicity (CNS delivery) | Medium | Medium | Use novel capsids (AAV5, AAV9 variants) with lower seroprevalence |
| Insufficient efficacy due to multiple parallel lysosomal defects | Medium | High | Combine with TFEB activators or GCase enhancement for synergistic benefit |
| Clinical trial enrollment (rare CHMP2B carriers) | High | Medium | Design basket trial across PD/FTD/ALS without requiring CHMP2B mutation |
| Small molecule drug-like properties (VPS4 activators) | Medium | High | Focus on [gene therapy](/therapeutics/gene-therapy-neurodegeneration) if small molecules prove challenging |

Actionable Next Steps

Lab Experiments

Generate iPSC-derived neurons from CHMP2B FTD patients and age-matched controls

Transduce with AAV-CHMP2A, AAV-CHMP4B, or AAV-VPS4A; measure MVB formation, lysosomal protease activity, and [alpha-synuclein](/proteins/alpha-synuclein) clearance

Establish high-content screen for VPS4 ATPase agonists (Z'=0.5+)

Test AAV-ESCRT-III in AAV-SNCA rat model (behavioral + histological endpoints)

Clinical Protocol Design

Design Phase 1/2 basket trial: PD + FTD + ALS ([alpha-synuclein](/proteins/alpha-synuclein) or TDP-43 proteinopathy)

Select primary endpoints: MDS-UPDRS (PD), CDR-SB (FTD), ALSFRS-R (ALS)

Enrichment biomarkers: RT-QuIC (synuclein), TDP-43 seed assay, CHMP2B carrier status

Company Partnership Opportunities

Voyager Therapeutics — AAV [gene therapy](/therapeutics/gene-therapy-neurodegeneration) platform, CNS delivery expertise

Denali Therapeutics — Lysosomal dysfunction focus, [blood-brain barrier](/entities/blood-brain-barrier) crossing technology

Ionis Pharmaceuticals — ASO delivery for intraneuronal targets

Spark Therapeutics / Roche — AAV [gene therapy](/therapeutics/gene-therapy-neurodegeneration) manufacturing and clinical execution

Grant Opportunities

NIH R01 — "ESCRT-III restoration as a novel disease-modifying strategy for synucleinopathies" ($500K/year direct)

CurePSP — "Targeting ESCRT-III dysfunction in PSP and FTD" ($150K/year)

Michael J. Fox Foundation — "Gene therapy for ESCRT-III in PD" ($500K)

ALSA — "ESCRT-III [neuroprotection](/therapeutics/neuroprotection) in [ALS](/diseases/amyotrophic-lateral-sclerosis)/[FTD](/diseases/frontotemporal-dementia)" ($150K/year)

📖 View canonical wiki page →

Related Entities

ideas-payload-escrthost-iii-neuroprotection-therapy

▸Metadataorigin_type: v1_polymorphic_backfill

slug	ideas-payload-escrthost-iii-neuroprotection-therapy
kg_node_id	None
entity_type	idea
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-c910d3a9cab6
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'ideas-payload-escrthost-iii-neuroprotection-therapy'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

548

Outgoing

719

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

ESCRT-III Neuroprotection Therapy for Neurodegeneration

ESCRT-III Neuroprotection Therapy for Neurodegeneration

Cross-Linking Context

ESCRT-III Neuroprotection Therapy for Neurodegeneration

Cross-Linking Context

Overview

Mechanism of Action

ESCRT-III Biology

Pathological Implication in Neurodegeneration

Therapeutic Mechanism

10-Dimension Rubric Score

Disease Applicability

Development Pathway

Preclinical (Years 1-2)

IND-Enabling (Years 2-3)

Clinical Development

Competitive Landscape

Preclinical Evidence Summary

Evidence Table: ESCRT-III as Neurodegeneration Target

Key Experimental Designs

Feasibility Assessment Update

Additional Evidence Gaps

Key Academic Centers and Collaborators

Risks and Mitigation

Actionable Next Steps

Lab Experiments

Clinical Protocol Design

Company Partnership Opportunities

Grant Opportunities

💬 Discussion